Pliant Therapeutics to Participate in the BTIG Biotechnology Conference

Rhea-AI Summary

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a biotechnology company focused on fibrosis treatments, will participate in the 2021 BTIG Virtual Biotechnology Conference from August 9-10, 2021. The company's CEO, Bernard Coulie, will engage in a fireside chat on August 10 at 3:30 p.m. EST. Pliant's lead candidate, PLN-74809, is an oral therapy for idiopathic pulmonary fibrosis and primary sclerosing cholangitis, having received Orphan Drug Designation from the FDA. The company is also advancing treatments for nonalcoholic steatohepatitis through partnerships and has additional preclinical oncology and muscular dystrophy programs.

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced its participation in the 2021 BTIG Virtual Biotechnology Conference to be held August 9 – 10, 2021.

Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will participate in a fireside chat on Tuesday, August 10, 2021, at 3:30 p.m. EST / 12:30 p.m. PST and, along with members of Pliant’s senior management team, will conduct one-on-one meetings with members of the investment community.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small molecule dual selective inhibitor of α_vß₆ and α_vß₁ integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 in the lead indications of IPF, PSC. Pliant has also developed PLN-1474, a small molecule selective inhibitor of α_vß₁ for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis, which Pliant has transferred to Novartis pursuant to our development partnership. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com

 

FAQ

What is Pliant Therapeutics' upcoming event related to PLRX in August 2021?

Pliant Therapeutics will participate in the 2021 BTIG Virtual Biotechnology Conference from August 9-10, 2021.

Who will represent Pliant Therapeutics at the BTIG Conference on August 10, 2021?

CEO Bernard Coulie will participate in a fireside chat at the conference on August 10 at 3:30 p.m. EST.

What are Pliant's main drug candidates mentioned in the press release?

Pliant's main drug candidates include PLN-74809 for idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

What FDA designation has PLN-74809 received?

PLN-74809 has received Orphan Drug Designation from the U.S. FDA for both idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

What other programs is Pliant Therapeutics currently developing?

Pliant is developing PLN-1474 for nonalcoholic steatohepatitis and has two preclinical programs targeting oncology and muscular dystrophies.